BMJ

Guidelines for musculoskeletal ultrasound in rheumatology

aDepartment of Rheumatology and Clinical Immunology, Charité University Hospital, Humboldt University, Berlin, Germany, bDepartment of Rheumatology and Physical Medicine, University Hospital, Zurich, ...
BMJ

Novel and reliable DACTylitis glObal Sonographic (DACTOS) score in psoriatic arthritis

Correspondence to Professor Annamaria Iagnocco, Scienze Cliniche e Biologiche, Università degli Studi di Torino, Turin 10043, Italy; annamaria.iagnocco1{at}gmail.com Objectives Dactylitis is one of ...
BMJ

ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: results from the SPondyloArthritis Caught Early (SPACE)-cohort and from the Assessment of ...

Correspondence to Professor Désirée van der Heijde, Department of Rheumatology, Leiden University Medical Center,P.O. Box 9600, 2300 RC Leiden, The Netherlands; mail{at}dvanderheijde.nl Objective To ...
BMJ

Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs ...

Objective To assess the efficacy/safety of ivarmacitinib, a selective Janus kinase (JAK) 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis (RA) who had an inadequate ...
BMJ

FRI0693 Fears and misconceptions of women with chronic rheumatic diseases on their journey to motherhood

Background: Recent EULAR ‘Points to Consider’ provide guidance on management and treatment of Women of Childbearing Age (WoCBA) with chronic rheumatic diseases (CRD: RA, axSpA, PsA). However, it is ...
BMJ

Physician global assessment in systemic lupus erythematosus: can we rely on its reliability?

We read with great interest the recent paper by Aranow et al 1 about the impact of laboratory results on scoring of the Physician Global Assessment (PGA) of disease activity in systemic lupus ...
BMJ

Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland

We read with interest the recent article by Singh and Cleveland on the hypersensitivity risk of allopurinol (ALP) and febuxostat (FBX) compared with colchicine.1 A common challenge when using ALP, ...
BMJ

Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness

Objective Considering the diverse aetiologies and immunodysregulatory statuses observed in each patient with rheumatoid arthritis (RA), stratification based on peripheral blood immunophenotyping holds ...
BMJ

Vascular occlusion for optimising the functional improvement in patients with knee osteoarthritis: a randomised controlled trial

Objectives Knee osteoarthritis (KOA) is a leading cause of global disability with conventional exercise yielding only modest improvements. Here we aimed to investigate the benefits of integrating ...
BMJ

OP0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial

Background Interleukin-23 (IL-23), a key regulator of multiple effector cytokines, has been implicated in the pathogenesis of psoriatic lesions, synovitis, enthesitis, and bone erosion. Risankizumab ...
BMJ

Is a 1-year course of methotrexate in patients with arthralgia at-risk for rheumatoid arthritis cost-effective? A cost-effectiveness analysis of the randomised, placebo ...

Objectives Rheumatoid arthritis (RA) has a considerable disease burden with life-long physical limitations, reduced work productivity and high societal costs. Trials on arthralgia at-risk for RA are ...
BMJ

Antinuclear antibody as entry criterion for classification of systemic lupus erythematosus: pitfalls and opportunities

Antinuclear antibodies (ANAs) are helpful to support the diagnosis of ANA-associated systemic rheumatic diseases (AASRD). Pisetsky et al recently reported on the variability of ANA detection, with ...